PI3K Signaling Pathways as a Molecular Target for Glioblastoma Multiforme-Reference-Cited by-同舟云学术

PI3K Signaling Pathways as a Molecular Target for Glioblastoma Multiforme

Published:2024-01 Issue:1 Volume:25 Page:12-26
ISSN:1389-2037
Container-title:Current Protein & Peptide Science
language:en
Short-container-title:CPPS

Author:

da Silva Andressa Letícia Lopes¹²,de Araújo Thiago Pina Goes¹,de Albuquerque Ferreira Shakira Cavalcante¹,Leite Anderson Brandão¹,da Silva João Kaycke Sarmento¹,Albuquerque Lilyana Waleska Nunes¹,de Lima Ana Rachel Vasconcelos¹,Silva Barros Herbert Charles³,Silva Leandro Rocha⁴,da Silva-Júnior Edeildo Ferreira⁴²,de Araújo-Júnior João Xavier²,Neto Vivaldo Moura⁵,de Queiroz Aline Cavalcanti¹,Alexandre-Moreira Magna Suzana¹

Affiliation:

1. Laboratory of Pharmacology and Immunity, Institute of Biological and Health Sciences, Federal University of Alagoas, AC. Simões campus, Maceió, 57072-900, Brazil

2. Laboratory of Medicinal Chemistry, Institute of Pharmaceutical Sciences, Federal University of Alagoas, AC. Simões campus, Maceió, 57072-900, Brazil

3. Municipal Secretary of Health of Maceio, Governo do estado de Alagoas, Brazil

4. Biological and Molecular Chemistry Research Group, Institute of Chemistry and Biotechnology, Federal University of Alagoas, AC. Simões campus, Maceió, 57072-900, Brazil

5. Paulo Niemeyer State Brain Institute, Study and Research Center, Brain Biomedicine Laboratory, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil

Abstract

Abstract: Glioblastoma multiforme (GBM) is the most common type of cancer that affects the central nervous system (CNS). It currently accounts for about 2% of diagnosed malignant tumors worldwide, with 296,000 new cases reported per year. The first-choice treatment consists of surgical resection, radiotherapy, and adjuvant chemotherapy, which increases patients' survival by 15 months. New clinical and pre-clinical research aims to improve this prognosis by proposing the search for new drugs that effectively eliminate cancer cells, circumventing problems such as resistance to treatment. One of the promising therapeutic strategies in the treatment of GBM is the inhibition of the phosphatidylinositol 3-kinase (PI3K) pathway, which is closely related to the process of tumor carcinogenesis. This review sought to address the main scientific studies of synthetic or natural drug prototypes that target specific therapy co-directed via the PI3K pathway, against human glioblastoma.

Publisher

Bentham Science Publishers Ltd.

Subject

Cell Biology,Molecular Biology,Biochemistry,General Medicine